| Title |
The role of the breast cancer surgeon in personalized cancer care: clinical utility of the 21-gene assay
|
|---|---|
| Published in |
American Journal of Surgery, April 2012
|
| DOI | 10.1016/j.amjsurg.2011.07.024 |
| Pubmed ID | |
| Authors |
Christine Laronga, Jay K. Harness, Matthew Dixon, Patrick I. Borgen |
| Abstract |
Breast cancer surgeons represent the first line of defense for many patients battling this disease. They often have the first contact to discuss treatment options with the patient after diagnosis. However, the potential impact of this consultation has evolved with the arrival of commercialized multigene prognostic and predictive tests that continue to reshape the landscape of breast cancer management, including modern surgical practice. |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 23% |
| Researcher | 3 | 14% |
| Professor | 3 | 14% |
| Student > Master | 2 | 9% |
| Student > Bachelor | 1 | 5% |
| Other | 5 | 23% |
| Unknown | 3 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 55% |
| Agricultural and Biological Sciences | 3 | 14% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Computer Science | 1 | 5% |
| Engineering | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 4 | 18% |